South Carolina is currently home to 1173 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Healing, Equity, Advocacy and Respect for Mamas
NCT06273436
Recruiting
The goal of the proposed research is to test the comparative effectiveness of AIM safety bundles for post-partum women delivered in-person vs. via text/phone to improve early detection of and timely care for complications during the first six weeks postpartum for women experiencing significant health disparities.
Gender:
FEMALE
Ages:
Between 16 years and 49 years
Trial Updated:
01/13/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Postpartum Complication
Register for Updates
Metabolically Fit CD19 CAR T-cell Therapy with CD34 Selection in Patients with CD19+ Relapsed/Refractory NHL, CLL/SLL
NCT05702853
Recruiting
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina
Conditions: B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Register for Updates
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
NCT05456880
Recruiting
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
01/09/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Sickle Cell Disease
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Beaufort Memorial Hospital, Beaufort, South Carolina
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Use of a Cloud-connected Remote Blood Pressure Monitoring Program During the Postpartum Period for Hypertensive Women
NCT06096701
Recruiting
Hypertensive disorders (HD), including preeclampsia, gestational hypertension, chronic hypertension, and chronic hypertension with superimposed preeclampsia, affect around 10-20% of pregnant women in the United States and are significantly associated with maternal mortality and morbidity, particularly in the postpartum period. The prevalence of HD is on the rise in the United States and has increased from 13% in 2017 to 16% in 2019 owing to an increase in advanced maternal age, obesity, and diab... Read More
Gender:
FEMALE
Ages:
Between 18 years and 54 years
Trial Updated:
01/08/2025
Locations: Prisma Health Richland, Columbia, South Carolina
Conditions: Hypertensive Disorder
Register for Updates
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
NCT06039176
Recruiting
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding an... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/08/2025
Locations: MUSC, Charleston, South Carolina
Conditions: LVAD, Frailty, GI Bleed, Right Heart Failure, Infections, Hypertension, Arrhythmias, Stroke
Register for Updates
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
NCT06700460
Recruiting
Evaluating outcomes after bilateral implantation of ICLs or bilateral LASIK as treatment options for the correction or reduction of myopia with or without astigmatism.
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
01/07/2025
Locations: Carolina Eyecare Physicians, Mt. Pleasant, South Carolina
Conditions: Myopia
Register for Updates
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
NCT05550298
Recruiting
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: * To develop and validate a classifier based on pre-transplant immunological profi... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
01/06/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
Register for Updates
HVIP Outcomes and Stakeholder Insights
NCT06582953
Recruiting
The study's goal is to perform an evaluation of a Southeastern hospital violence intervention program (HVIP) that includes comprehensive patient outcomes, perceived benefits and opportunities for improvement of an HVIP from the perspectives of multiple stakeholders including patients, family members and healthcare providers.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/03/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Firearm Injury, Violence, Physical
Register for Updates
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
FEMALE
Ages:
Between 15 years and 55 years
Trial Updated:
01/02/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
NCT05814666
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Prisma Health Cancer Institute, Greenville, South Carolina
Conditions: HNSCC
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates